59.97
Halozyme Therapeutics Inc stock is traded at $59.97, with a volume of 2.47M.
It is down -0.18% in the last 24 hours and up +15.28% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$60.08
Open:
$59.9
24h Volume:
2.47M
Relative Volume:
0.99
Market Cap:
$7.39B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
19.86
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+2.04%
1M Performance:
+15.28%
6M Performance:
+5.88%
1Y Performance:
+8.52%
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HALO
Halozyme Therapeutics Inc
|
59.97 | 7.40B | 947.36M | 392.47M | 392.71M | 3.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-10-25 | Resumed | Goldman | Neutral |
May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Feb-29-24 | Initiated | TD Cowen | Outperform |
Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
Jul-24-23 | Initiated | H.C. Wainwright | Buy |
May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-27-23 | Resumed | Berenberg | Buy |
Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
Dec-21-22 | Resumed | Morgan Stanley | Overweight |
Nov-28-22 | Initiated | Wells Fargo | Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Overweight |
May-23-22 | Initiated | SVB Leerink | Outperform |
Jun-14-21 | Initiated | Evercore ISI | Outperform |
May-17-21 | Initiated | SVB Leerink | Outperform |
May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-21-21 | Reiterated | The Benchmark Company | Buy |
Dec-17-20 | Initiated | Berenberg | Buy |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Jul-01-20 | Initiated | The Benchmark Company | Buy |
Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-08-20 | Initiated | Goldman | Buy |
Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
Oct-19-18 | Resumed | Piper Jaffray | Neutral |
May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-24-18 | Initiated | Goldman | Neutral |
Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
Nov-03-16 | Initiated | Deutsche Bank | Buy |
Dec-04-15 | Initiated | Wells Fargo | Outperform |
Nov-18-15 | Initiated | Citigroup | Buy |
Sep-22-15 | Initiated | Barclays | Overweight |
Jun-22-15 | Reiterated | JP Morgan | Overweight |
Mar-03-15 | Reiterated | UBS | Buy |
Feb-18-15 | Reiterated | MLV & Co | Buy |
Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
What catalysts could drive Halozyme Therapeutics Inc. stock higher in 2025Stock Strategy Signals For Consistent Profits - jammulinksnews.com
Halozyme Therapeutics Insider Lowered Holding By 38% During Last Year - 富途牛牛
Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT - MSN
How Halozyme Therapeutics Inc. stock performs during market volatilitySmart Money Tracking Signal Generator Activated - metal.it
Short Interest Drops in Halozyme Therapeutics Inc. After RallyOversold Recovery Opportunity Stocks Attract Buyers - metal.it
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Halozyme Therapeutics Inc. Outperforms Peers on Volume MetricsPrice Action Based Buy Opportunity List Published - metal.it
Why Halozyme Therapeutics Inc. stock attracts strong analyst attentionProfit Target Stock Opportunity Monitor Activated - metal.it
How Resilient Is Halozyme Therapeutics Inc. Stock During Economic DownturnsMarket Entry and Exit Point Tips From Traders - metal.it
Does Halozyme Therapeutics Inc. stock perform well during market downturnsBuild a strong portfolio for growth and safety - jammulinksnews.com
What is Halozyme Therapeutics Inc. company’s growth strategyOutstanding capital returns - jammulinksnews.com
Published on: 2025-07-28 01:53:45 - jammulinksnews.com
Halozyme’s Promising Cancer Study: A Potential Game-Changer in Oncology - TipRanks
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Should I buy Halozyme Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com
What risks could impact Halozyme Therapeutics Inc. stock performanceConsistently superior profits - jammulinksnews.com
What analysts say about Halozyme Therapeutics Inc. stockExceptional return forecasts - PrintWeekIndia
38% Of This Halozyme Therapeutics Insider's Holdings Were Sold - simplywall.st
Is Halozyme Therapeutics Inc. stock overhyped or has real potentialBreakout profit opportunities - jammulinksnews.com
Halozyme to Report Second Quarter 2025 Financial and Operating Results - Eastern Progress
BlackRock, Inc. Adjusts Holdings in Halozyme Therapeutics Inc. - GuruFocus
Halozyme Therapeutics Inc. Stock Analysis and ForecastExceptional profit margins - Autocar Professional
Halozyme Therapeutics Says Myeloma Drug With Enhanze Delivery Technology Gets EU Approval - 富途牛牛
Is Halozyme Therapeutics Inc. a good long term investmentFree Risk Assessment Services - jammulinksnews.com
J&J Darzalex injectable cleared in EU for smouldering MM (JNJ) - Seeking Alpha
Halozyme says EU approves new indication for Janssen’s Darzalex Faspro - TipRanks
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma - WV News
What drives Halozyme Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - Yahoo Finance
Halozyme to Present Q2 2025 Financial Results After Market Close on August 5 - Stock Titan
Halozyme Stock Maintains Hold Rating Amid CMS Pricing Uncertainty and Regulatory Concerns. - AInvest
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):